Tandem Diabetes Stock Price, News & Analysis

Tandem Diabetes Care, Inc. (NASDAQ: TNDM) announced positive results from a multicenter study on the t:slim X2 insulin pump featuring Control-IQ technology for type 2 diabetes management. The study found significant improvements in glycemic control, with a 15% increase in time in range (3.6 hours/day). No hypoglycemia was reported. High satisfaction levels were observed among participants. The trial involved 30 adults across three centers. Notably, Control-IQ technology is not yet FDA-approved for type 2 diabetes use and was employed under an investigational device exemption.

Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leader in diabetes technology, will present a company update at the Piper Sandler 34th Annual Healthcare Conference on Wednesday, November 30, 2022, at 9:00 AM Eastern Time. The presentation will be available via live webcast, and an archive will be accessible for 30 days. More details can be found on Tandem's Investor Center under the “Events & Presentations” section. Tandem is known for its innovative insulin delivery solutions, including the t:slim X2 insulin pump.

Tandem Diabetes Care reported its Q3 2022 results, highlighting a 35% increase in its worldwide installed customer base, surpassing 400,000. Total sales rose 14% to $204.5 million, driven by a nearly 70% surge in U.S. renewal pump shipments. Despite a gross profit increase of 8% to $104.4 million, the company faced a GAAP net loss of $49 million, compared to a profit in the prior year. The updated 2022 guidance estimates non-GAAP sales between $800 million and $805 million, down from previous expectations, amid cautious market conditions.

Tandem Diabetes Care, Inc. (NASDAQ: TNDM) will present updates at several investor conferences in November 2022. The presentations will take place at the Credit Suisse 31st Annual Healthcare Conference on November 8 at 4:25 PM ET, the Jefferies London Healthcare Conference on November 15 at 12:20 PM GMT, and the Stifel 2022 Healthcare Conference on November 16 at 4:45 PM ET. All presentations will be webcast live with an archive available for 30 days on their Investor Center website.

Tandem Diabetes Care, Inc. (NASDAQ: TNDM) plans to announce its third quarter 2022 results post-market close on November 2, 2022. A conference call and webcast, scheduled for 4:30 PM ET, will discuss the financial and operational results. Investors can access the live webcast via the Investor Center on their website. An archived version will be available for 30 days following the event.

As a prominent insulin delivery and diabetes technology firm, Tandem continues to innovate with products like the t:slim X2 insulin pump featuring Control-IQ technology.

Tandem Diabetes Care, Inc. (NASDAQ: TNDM) will present at two upcoming investor conferences: the Wells Fargo Healthcare Conference on September 8, 2022, at 1:55 PM ET and Baird’s Global Healthcare Conference on September 13, 2022, at 9:40 AM ET. Both presentations will be webcast live, with archived recordings available for 30 days on their Investor Center website. Tandem focuses on innovative diabetes solutions, offering products like the t:slim X2 insulin pump with Control-IQ technology.

Tandem Diabetes Care (NASDAQ:TNDM) announced that users of its t:slim X2 insulin pump have delivered over 1 million insulin boluses via the t:connect app within a month of its launch. This app, the first FDA-cleared one for initiating insulin delivery on smartphones, supports both iOS and Android on approximately 30 devices. Users can activate this feature at no additional cost. CEO John Sheridan emphasized the importance of innovative technology for improving diabetes management.

Tandem Diabetes Care (NASDAQ: TNDM) reported strong Q2 2022 results, with worldwide sales up 16% to $200.3 million and a 40% increase in its installed base, totaling over 375,000 customers. U.S. sales rose 14% to $145.7 million, and gross profit increased 10% to $101.9 million. However, the company updated its 2022 sales guidance down to $835 million - $845 million, lower than previous estimates. Furthermore, a net loss of $15.1 million was reported compared to a $4.0 million income in the same quarter last year. Adjusted EBITDA also saw a decline.

Tandem Diabetes Care (NASDAQ:TNDM) has acquired Capillary Biomedical, an infusion set developer, aiming to enhance its insulin delivery portfolio. The acquisition focuses on expanding options for insulin pump wearability, with a commitment to developing innovative solutions that extend wear time and reduce user burden. Although the technology is still in development and not yet available commercially, the company sees potential synergies in integrating Capillary's solutions into its product offerings. Financial terms of the transaction remain undisclosed.